Advanced Therapeutics : Impact Factor & More
eISSN: 2366-3987pISSN: 2366-3987
Share this on:
Key Metrics
CiteScore 
7
Impact Factor
< 5
SJR
Q4Pharmacology
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Advanced Therapeutics
Advanced Therapeutics Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | Wiley-Blackwell |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 3900 |
| General Details | |
| Publication Details |
View less
Planning to publish in Advanced Therapeutics ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Advanced Therapeutics
Mitochondria‐Targeted Curcumin Delivery: Therapeutic Strategies for Mitochondrial Dysfunction‐Related Disorders
- 1 Apr 2026
- Advanced Therapeutics
High‐Efficiency, Short‐Pulse Electrothermal Cancer Therapy Utilizing Polyethylene Glycol (PEG‐) Based Titanium Carbide (Ti <sub>3</sub> C <sub>2</sub> ) MXene Nanomaterials
- 1 Apr 2026
- Advanced Therapeutics
Targeting Ferroptosis for Cancer Immunotherapy: Molecular Mechanisms, Immune Microenvironment Crosstalk, and Clinical Translation Prospects
- 1 Apr 2026
- Advanced Therapeutics
Structure‐Governed MXene Quantum Dots for Cancer Theranostics: From Quantum Confinement to Tumor‐Selective Catalytic and Photothermal Activation
- 1 Apr 2026
- Advanced Therapeutics
Title not available
- 1 Apr 2026
- Advanced Therapeutics
Issue Information (Adv. Therap. 4/2026)
- 27 Mar 2026
- Advanced Therapeutics
Mitochondria‐Targeted Curcumin Delivery: Therapeutic Strategies for Mitochondrial Dysfunction‐Related Disorders
- 1 Apr 2026
- Advanced Therapeutics
High‐Efficiency, Short‐Pulse Electrothermal Cancer Therapy Utilizing Polyethylene Glycol (PEG‐) Based Titanium Carbide (Ti <sub>3</sub> C <sub>2</sub> ) MXene Nanomaterials
- 1 Apr 2026
- Advanced Therapeutics
Targeting Ferroptosis for Cancer Immunotherapy: Molecular Mechanisms, Immune Microenvironment Crosstalk, and Clinical Translation Prospects
- 1 Apr 2026
- Advanced Therapeutics
Structure‐Governed MXene Quantum Dots for Cancer Theranostics: From Quantum Confinement to Tumor‐Selective Catalytic and Photothermal Activation
- 1 Apr 2026
- Advanced Therapeutics
Title not available
- 1 Apr 2026
- Advanced Therapeutics
Issue Information (Adv. Therap. 4/2026)
- 27 Mar 2026
- Advanced Therapeutics
FAQs on Advanced Therapeutics
How long has Advanced Therapeutics been actively publishing? 
What is the publishing frequency of Advanced Therapeutics?
How many articles did Advanced Therapeutics publish last year?
What is the eISSN & pISSN for Advanced Therapeutics?
What is Citescore for Advanced Therapeutics?
What is the SJR for Advanced Therapeutics?
Who is the publisher of Advanced Therapeutics?
